Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Gasmi, 2020, Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic, Clin. Immunol., 215, 108409, 10.1016/j.clim.2020.108409 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med., 382, 1708, 10.1056/NEJMoa2002032 Grasselli, 2020, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA, 323, 1574, 10.1001/jama.2020.5394 Goyal, 2020, Clinical characteristics of Covid-19 in New York City, N. Engl. J. Med., 382, 2372, 10.1056/NEJMc2010419 Llitjos, 2020, High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients, J. Thromb. Haemost., 18, 1743, 10.1111/jth.14869 Helms, 2020, Neurologic features in severe SARS-CoV-2 infection, N. Engl. J. Med., 382, 2268, 10.1056/NEJMc2008597 Fabrizi, 2020, COVID-19 and acute kidney injury: a systematic review and meta-analysis, Pathogens, 9, 10.3390/pathogens9121052 Argenziano, 2020, Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series, BMJ (Clinical research ed.), 369 Fisher, 2020, AKI in hospitalized patients with and without COVID-19: a comparison study, J. Am. Soc. Nephrol., 31, 2145, 10.1681/ASN.2020040509 Hirsch, 2020, Acute kidney injury in patients hospitalized with COVID-19, Kidney Int., 98, 209, 10.1016/j.kint.2020.05.006 Chan, 2021, AKI in hospitalized patients with COVID-19, J. Am. Soc. Nephrol., 32, 151, 10.1681/ASN.2020050615 Coca, 2012, Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis, Kidney Int., 81, 442, 10.1038/ki.2011.379 Nugent, 2021, Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19, JAMA Netw. Open, 4, 10.1001/jamanetworkopen.2021.1095 Delorey, 2021, COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets, Nature, 595, 107, 10.1038/s41586-021-03570-8 Gavriilaki, 2020, Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily, Br. J. Haematol., 189, e227, 10.1111/bjh.16783 Satyam, 2020, Curb complement to cure COVID-19, Clin. Immunol., 221, 108603, 10.1016/j.clim.2020.108603 Song, 2020, COVID-19, microangiopathy, hemostatic activation, and complement, J. Clin. Invest., 130, 3950 Noris, 2020, The case of complement activation in COVID-19 multiorgan impact, Kidney Int., 98, 314, 10.1016/j.kint.2020.05.013 Pfister, 2020, Complement activation in kidneys of patients with COVID-19, Front. Immunol., 11, 594849, 10.3389/fimmu.2020.594849 de Nooijer, 2021, Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes, J. Infect. Dis., 223, 214, 10.1093/infdis/jiaa646 Skendros, 2020, Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis, J. Clin. Invest., 130, 6151, 10.1172/JCI141374 Mastaglio, 2020, The first case of COVID-19 treated with the complement C3 inhibitor AMY-101, Clin. Immunol., 215, 108450, 10.1016/j.clim.2020.108450 Mastellos, 2020, Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy, Clin. Immunol., 220, 108598, 10.1016/j.clim.2020.108598 Al-Bataineh, 2017, Novel roles for mucin 1 in the kidney, Curr. Opin. Nephrol. Hypertens., 26, 384, 10.1097/MNH.0000000000000350 Kost-Alimova, 2020, A High-content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury, Cell Rep. Med., 1, 100137, 10.1016/j.xcrm.2020.100137 Pamuk, 2010, Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion, Am. J. Physiol. Gastroint. Liver Physiol., 299, G391, 10.1152/ajpgi.00198.2010 Pamuk, 2015, Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model, Clin. Exp. Rheumatol., 33, S15 Braselmann, 2006, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation, J. Pharmacol. Exp. Ther., 319, 998, 10.1124/jpet.106.109058 Antenucci, 2018, Phosphorylated immunoreceptor tyrosine-based activation motifs and integrin cytoplasmic domains activate spleen tyrosine kinase via distinct mechanisms, J. Biol. Chem., 293, 4591, 10.1074/jbc.RA117.000660 Chauhan, 2012, Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells, Clin. Exp. Immunol., 167, 235, 10.1111/j.1365-2249.2011.04505.x Strich, 2020, Fostamatinib inhibits neutrophils extracellular traps induced by COVID-19 patient plasma: a potential therapeutic, J. Infect. Dis., 223, 981, 10.1093/infdis/jiaa789 Kitamoto, 2013, MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors, Oncogene, 32, 4614, 10.1038/onc.2012.478 Chakraborty, 2006, Hypoxia regulates cross-talk between syk and lck leading to breast cancer progression and angiogenesis *, J. Biol. Chem., 281, 11322, 10.1074/jbc.M512546200 Jang, 2021, Spleen tyrosine kinase regulates crosstalk of hypoxia-inducible factor-1α and nuclear factor (erythroid-derived2)-like 2 for B cell survival, Int. Immunopharmacol., 95, 107509, 10.1016/j.intimp.2021.107509 Serebrovska, 2020, Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets, Acta Pharmacol. Sin., 41, 1539, 10.1038/s41401-020-00554-8 Gusarova, 2011, Hypoxia leads to Na,K-ATPase downregulation via Ca(2+) release-activated Ca(2+) channels and AMPK activation, Mol. Cell. Biol., 31, 3546, 10.1128/MCB.05114-11 Racioppi, 2008, Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveller, Trends Immunol., 29, 600, 10.1016/j.it.2008.08.005 Greka, 2011, Balancing calcium signals through TRPC5 and TRPC6 in podocytes, J. Am. Soc. Nephrol., 22, 1969, 10.1681/ASN.2011040370 Ichinose, 2016, Lupus nephritis IgG induction of calcium/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function, Arthritis Rheum., 68, 944, 10.1002/art.39499 Maeda, 2018, CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease, J. Clin. Invest., 128, 3445, 10.1172/JCI99507 Brook, 2021, Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients, Abdominal Radiol., 46, 1263, 10.1007/s00261-020-02753-7 Matsumoto, 2017, C3a enhances the formation of intestinal organoids through C3aR1, Front. Immunol., 8, 10.3389/fimmu.2017.01046 Satyam, 2020, Complement deposition on the surface of RBC after trauma serves a biomarker of moderate trauma severity: a prospective study, Shock, 53, 16, 10.1097/SHK.0000000000001348 Satyam, 2019, Complement and coagulation cascades in trauma, Acute Med. Surgery, 6, 329, 10.1002/ams2.426 Satyam, 2017, Intracellular activation of complement 3 is responsible for intestinal tissue damage during mesenteric ischemia, J. Immunol., 198, 788, 10.4049/jimmunol.1502287 Kudose, 2020, Kidney biopsy findings in patients with COVID-19, J. Am. Soc. Nephrol., 31, 1959, 10.1681/ASN.2020060802 Golmai, 2020, Histopathologic and Ultrastructural findings in postmortem kidney biopsy material in 12 patients with AKI and COVID-19, J. Am. Soc. Nephrol., 31, 1944, 10.1681/ASN.2020050683 Santoriello, 2020, Postmortem kidney pathology findings in patients with COVID-19, J. Am. Soc. Nephrol., 31, 2158, 10.1681/ASN.2020050744 Tsokos, 2004, Autoimmunity, complement activation, tissue injury and reciprocal effects, Curr. Dir. Autoimmun., 7, 149, 10.1159/000075691 Wang, 2021, Diverse functional autoantibodies in patients with COVID-19, Nature, 595, 283, 10.1038/s41586-021-03631-y Satyam, 2021, Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19, Clin. Immunol., 226, 108716, 10.1016/j.clim.2021.108716 Gavriilaki, 2021, Genetic justification of severe COVID-19 using a rigorous algorithm, Clin. Immunol., 226, 108726, 10.1016/j.clim.2021.108726 Pastor, 2013, Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression, Hum. Immunol., 74, 1225, 10.1016/j.humimm.2013.05.005 Gibier, 2017, Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1863, 1336, 10.1016/j.bbadis.2017.03.023 Pastor-Soler, 2015, Muc1 is protective during kidney ischemia-reperfusion injury, Am. J. Physiol. Renal. Physiol., 15, F1452, 10.1152/ajprenal.00066.2015 Otomo, 2015, Cutting edge: nanogel-based delivery of an inhibitor of CaMK4 to CD4+ T cells suppresses experimental autoimmune encephalomyelitis and lupus-like disease in mice, J. Immunol., 195, 5533, 10.4049/jimmunol.1501603 Geahlen, 2014, Getting Syk: spleen tyrosine kinase as a therapeutic target, Trends Pharmacol. Sci., 35, 414, 10.1016/j.tips.2014.05.007 Schuringa, 2001, C-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE), Cytokine, 14, 78, 10.1006/cyto.2001.0856 McAdoo, 2020, Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model, Kidney Int., 97, 1196, 10.1016/j.kint.2019.12.014 McAdoo, 2018, Role of the spleen tyrosine kinase pathway in driving inflammation in IgA nephropathy, Semin. Nephrol., 38, 496, 10.1016/j.semnephrol.2018.05.019 Shi, 2006, Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis, Blood, 107, 4554, 10.1182/blood-2005-09-3616 Leroy, 2002, Expression of human mucin genes in normal kidney and renal cell carcinoma, Histopathology, 40, 450, 10.1046/j.1365-2559.2002.01408.x d’Alessandro, 2020, Serum KL-6 levels in pulmonary Langerhans’ cell histiocytosis, Eur. J. Clin. Investig., 50, 10.1111/eci.13242 Syrkina, 2017, Dual role of the extracellular domain of human Mucin MUC1 in metastasis, J. Cell. Biochem., 118, 4002, 10.1002/jcb.26056 Merle, 2015, Complement system part I - molecular mechanisms of activation and regulation, Front. Immunol., 6, 262, 10.3389/fimmu.2015.00262 Elsner, 1994, C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils, Eur. J. Immunol., 24, 518, 10.1002/eji.1830240304 Nie, 2016, Mucin-1 increases renal TRPV5 activity in vitro, and urinary level associates with calcium nephrolithiasis in patients, J. Am. Soc. Nephrol., 27, 3447, 10.1681/ASN.2015101100 Kulathu, 2008, The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development, EMBO J., 27, 1333, 10.1038/emboj.2008.62 Rao, 2013, Spleen tyrosine kinase (Syk)-dependent calcium signals mediate efficient CpG-induced exocytosis of tumor necrosis factor alpha (TNFalpha) in innate immune cells, J. Biol. Chem., 288, 12448, 10.1074/jbc.M113.454405 Ferretti, 2018, Calcium/Calmodulin kinase IV controls the function of both T cells and kidney resident cells, Front. Immunol., 9, 2113, 10.3389/fimmu.2018.02113 Li, 2019, MiR-129-5p inhibits liver cancer growth by targeting calcium calmodulin-dependent protein kinase IV (CAMK4), Cell Death Dis., 10, 789, 10.1038/s41419-019-1923-4 Satyam, 2020, Cell-derived extracellular matrix-rich biomimetic substrate supports podocyte proliferation, differentiation, and maintenance of native phenotype, Adv. Funct. Mater., 30, 1908752, 10.1002/adfm.201908752